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The poly(ADP-ribose) polymerase (PARP) enzymes play a key role in the regulation of cellular processes 
(e.g., DNA damage repair, genomic stability). It has been shown that PARP inhibitors (PARPIs) are selectively 
cytotoxic against cells having dysfunctions in genes involved in DNA repair mechanisms (synthetic lethality). 
Drug-induced PARP inhibition potentiates the activity of anticancer drugs such as 5-fluorouracil in enhancing 
DNA damage, whose repair involves PARP-1 activity. The aim of this study was to evaluate the inhibitory 
effects of a novel PARPI, HYDAMTIQ, on growth in human tumor cell lines characterized by different fea-
tures with regard to DNA damage response pathways (BRCA mutational status, microsatellite status, and ATM 
expression level) and degree of sensitivity/resistance to 5-fluorouracil. HYDAMTIQ showed a more potent 
inhibitory effect on cell growth in a BRCA2 mutant cell line (CAPAN-1) compared with wild-type cells (C2-6, 
C2-12, and C2-14 CAPAN-1 clones, and MCF-7). No statistically significant difference was observed after 
HYDAMTIQ exposure between cells having a different MS status or a different MRE11 mutational status. 
HYDAMTIQ induced greater antiproliferative effects in SW620 cells expressing a low level of ATM than in 
H630 cells expressing a high level of ATM. Finally, the combination of HYDAMTIQ and 5-fluorouracil exerted 
a synergistic effect on the inhibition of SW620 cell growth and an antagonistic effect on that of H630 cell 
growth. Our results show that the novel PARP inhibitor HYDAMTIQ potently inhibits the growth of human 
tumor cells with defective DNA damage response pathways and exerts synergistic cytotoxicity in combina-
tion with 5-fluorouracil. These data provide relevant examples of synthetic lethality and evidence for further 
development of this novel PARPI.
Key words: PARP inhibitors (PARPIs); HYDAMTIQ; 5-Fluorouracil (5-FU); Human tumor cell lines; 
DNA damage response
INTRODUCTION
Poly(ADP-ribose) polymerases (PARPs) are a major 
family of proteins that catalyzes posttranslational modi-
fications [i.e., poly(ADP-ribosyl)ation and mono(ADP- 
ribosyl)ation (PARylation and MARylation, respec-
tively)]1. Such proteins use the NAD+ cofactor to trans-
fer an ADP-ribose group onto a specific protein acceptor 
with the concomitant release of nicotinamide2. Today, at 
least 17 members of this family of enzymes have been 
identified. PARPs regulate both nuclear and cytoplasmic 
processes, including DNA damage repair, transcription, 
cell cycle progression, unfolded protein response, mito-
sis, and cell death2.
The nuclear members (PARP-1–3) have been reported to 
be involved in several biological processes, including DNA 
damage. Since the effects of PARP inhibitors (PARPIs) on 
cancer cells are related to DNA damage, most research on 
PARPIs has focused on such PARPs. PARP-1 and PARP-2 
synthesize branched PAR polymers, whereas PARP-3 is a 
critical player in the stabilization of the mitotic spindle and 
in telomere integrity, notably by associating and regulating 
the mitotic components NuMA and tankyrase 13.
Emerging data suggest that PARP inhibition is a poten-
tially important strategy for managing a significant subset 
of tumors. The rationale for the use of PARPIs is based 
on the exploitation of synthetic lethality conferred to can-
cer cells by the copresence of an aberrant DNA damage 
response (DDR) gene and the PARPI4.
To date, only two PARPIs are approved for clinical 
use: olaparib and rucaparib. Olaparib received accelerated 
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approval by the FDA in pretreated ovarian cancer patients 
harboring germline BRCA mutations on the basis of 
favorable objective response rate and duration of response 
obtained in clinics5. Rucaparib has been recently approved 
for the treatment of platinum-sensitive BRCA-mutated 
advanced ovarian cancer patients who received more than 
two lines of platinum-based therapy and whose tumors 
show homologous recombination (HR) loss of heterozy-
gosity6. In cells with mutations in BRCA1 and/or BRCA2 
that are HR deficient, PARPIs stimulate DNA repair by 
the error-prone nonhomologous end joining recombina-
tion (NHEJ) mechanism. Thus, NHEJ is the major con-
tributor to the cytotoxicity observed in HR-deficient cells 
treated with PARPIs7.
The PARPI HYDAMTIQ, a hydroxyl derivative of 
thieno[2,3-c]isoquinolin-5(4H)-one, is a potent and selective 
PARP-1/2 inhibitor8,9. The neuroprotective10, antiasthmatic11, 
and anti-inflammatory12 properties of HYDAMTIQ have 
been investigated in in vivo experimental systems in relation 
to the fact that PARP-1 activation contributes to postische-
mic brain damage and facilitates the expression of tumor 
necrosis factors and other proinflammatory cytokines.
The present research investigates the potential anti-
cancer activity of HYDAMTIQ by studying the inhibi-
tory effects of HYDAMTIQ on the growth of a panel 
of human cancer cell lines characterized by differences 
in the mutational status of BRCA gene, microsatellite 
status, expression levels of ATM (ataxia-telangiectasia 
mutated), and degree of intrinsic sensitivity/resistance to 
5-fluorouracil (5-FU).
Cell lines received long-term exposure to HYDAMTIQ 
in order to closely mimic the exposure times that derive from 
the continuous oral administration of olaparib in clinics13,14.
MATERIALS AND METHODS
Drugs and Supplies
Olaparib was obtained from Selleck Chemicals 
(Munich, Germany); the novel PARPI HYDAMTIQ 
was provided by Prof. Pellicciari (University of Perugia) 
and TESPHARMA (Perugia, Italy). 5-FU and sulfor-
hodamine B (SRB) were obtained from Sigma-Aldrich 
(Milan, Italy). All the other chemicals were of analytical 
grade. RPMI-1640 and high-glucose DMEM cell culture 
mediums, fetal calf serum (FCS), trypsin-EDTA, anti-
biotics, and phosphate-buffered saline were obtained from 
Gibco (Milan, Italy).
The phospho-ATM (Ser1981) mouse monoclonal 
antibody was obtained from GeneTex (Irvine, CA, USA) 
and Alexa Fluor® 488 and 4,6-diamidino-2 phenylindole 
(DAPI) were from Abcam (Cambridge, UK).
Cell Lines and Culture Conditions
The human BRCA2-mutated pancreatic cancer cell 
line (CAPAN-1) sensitive to cisplatin and its clones (C2-6, 
C2-12, and C2 -14) characterized by secondary intragenic 
mutations in BRCA2 that restore the wild-type BRCA2 
reading frame and that confer resistance to cisplatin were 
a gift from Dr. Toshiyasu Taniguchi (Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA). The breast 
cancer cell line MCF-7 (BRCA1/2 wild type) and the col-
orectal cancer cell lines HCT-8, HCT-116, H630, LoVo, 
DLD-1 [microsatellite instable (MSI)], HT29, and SW620 
[microsatellite stable (MSS)] were obtained from ATCC) 
(Manassas, VA, USA). Cell lines were maintained in an 
appropriate culture medium (RPMI-1640 or high- glucose 
DMEM), supplemented with 10% FCS and antibiotics 
(penicillin, 100 U/ml; streptomycin, 100 µg/ml) at 37°C 
in a 5% CO2 humidified atmosphere and subcultured 
twice weekly.
Cell Growth Inhibition Studies
The antiproliferative effects of HYDAMTIQ and 
olaparib were evaluated on the growth of the studied 
human tumor cell lines by the SRB assay15. Briefly, 
exponentially growing cells were inoculated into 96-well 
microtiter plates at plating densities of 2 ´  103 cells/well. 
After cell inoculation, the microtiter plates were incu-
bated under standard culture conditions (37°C, 5% CO2, 
95% air, and 100% relative humidity) for 24 h prior 
to the addition of experimental drugs. After 24 h, the 
medium was removed and replaced with medium con-
taining PARPIs at concentrations ranging from 0.5 to 
50 mM for continuous exposures of 72, 144, or 240 h. 
The assay was completed by the addition of cold TCA. 
Cells were fixed in situ by 10% TCA and stained by SRB 
solution at 0.4% (w/v) in 1% acetic acid. After staining, 
unbound dye was removed by washing five times with 
1% acetic acid, and the plates were air dried. Bound stain 
was subsequently solubilized with 10 mM Tris base, and 
the absorbance was read on an automated plate reader at 
a wavelength of 540 nm.
The IC20, IC25, and IC50 resulting in a 20%, 25%, and 
50% reduction in the net protein content (as measured by 
SRB staining) in drug-treated cells compared to untreated 
control cells were determined after drug exposures.
The degree of resistance (R) to PARPIs is defined 
as the ratio between IC50 values obtained in BRCA1/2-
mutated, MSI, or lowest-ATM expression cell lines and 
the BRCA1/2 wild type, MSS, and highest-ATM expres-
sion cell lines, respectively. R values lower than 0.9 indi-
cate collateral sensitivity, and those between 0.9 and 1.1 
equal sensitivity and R values higher than 1.1 indicate 
cross-resistance16.
The growth inhibitory effects of the combination of 
PARPIs and 5-FU on SW620 and H630 have been stud-
ied using the IC25 of 5-FU (1 and 3 mM for H630 and 
SW620 cells, respectively) and the IC50 of HYDAMTIQ 
(20 and 45 mM for SW620 and H630 cells, respectively) 
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or of olaparib (5 and 30 mM for SW620 and H630, respec-
tively) and by exposing cells to drugs for 144 h.
The potential synergism between HYDAMTIQ and 
5-FU was evaluated using Drewinko’s fraction method16. 
The synergistic, additive, and antagonistic interactions 
were determined by the ratio between the cell growth 
following single-agent exposures (expected value) and 
the cell growth following drug-combination exposures 
(observed cell growth) (CI) as follows: CI < 0.9 synergism, 
CI from 0.9 to 1.1 additivity, and CI > 1.1 antagonism.
Immunofluorescence Analysis
Immunofluorescence analysis of baseline ATM protein 
levels was performed in duplicate in five human colon 
carcinoma cell lines (HCT-8, H630, SW620, LoVo, and 
HT29). By densitometry analysis of protein levels, the cell 
lines with the highest and lowest level of ATM were identi-
fied (H630 and SW620, respectively). Such cell lines were 
used in the experiments of expression modulation after 
long-term exposure (240 h) at 2 ´  CI50 of HYDAMTIQ.
Cells were grown in glass chamber slides at a start-
ing concentration of 0.75 ´  104 in 0.5 ml of complete cul-
ture medium for 4–5 days until confluence. Slides were 
washed twice with cold PBS and then fixed with cold 
100% methanol for 10 min at −20°C. Cells were then per-
meabilized with 0.1% Triton X-100 in PBS for 15 min.
After washing three times with PBS, the slides were 
blocked for 30 min in PBS containing 2% BSA at room 
temperature, and then incubated for 1 h with 1:1,000 dilu-
tion of phospho-ATM(Ser1981) antibody in 2% BSA/
PBS. After several washings with 0.1% Tween 20/PBS, 
bound antibodies were detected with a 1:200 dilution of 
goat anti-mouse secondary polyclonal antibody, FITC) 
conjugate (Abcam). Nuclei were counterstained with 
a 1:5,000 dilution of DAPI for 15 min. Representative 
images were acquired by an Olympus BX63 microscope 
coupled with a CellSens Dimension Imaging Software 
version 1.6 (Olympus, Milan, Italy).
The fluorescence intensity was determined in a semi-
quantitative way with densitometry analysis (ImageJ soft-
ware, NIH Image) normalizing for the number of cells per 
microscope field.
Statistical Analysis
Statistical analysis was performed employing Student’s 
t-test and Spearman test (GraphPad Prism v.5). Values of 
p < 0.05 were considered significant.
RESULTS
HYDAMTIQ Inhibitory Effects on the Growth of Tumor 
Cell Lines With Different Mutational Status of BRCA2
The inhibitory effects of HYDAMTIQ and olaparib 
were evaluated in the BRCA2-mutated CAPAN-1 cell 
lines, its C2-6, C2-12, and C2-14 clones characterized 
by secondary intragenic mutations in BRCA2 that restore 
the wild-type BRCA2 reading frame, and in the BRCA2 
wild-type MCF-7 cells after 72, 144, and 240 h of expo-
sure. Slightly higher IC50 values were observed with 
HYDAMTIQ compared with olaparib after 72 or 144 h of 
treatment, whereas after 240 h HYDAMTIQ and olaparib 
showed similar IC50 values (Table 1).
At all exposure times, HYDAMTIQ was signifi-
cantly more active at inhibiting CAPAN-1 cell growth 
compared to C2-6, C2-12, and C2-14 BRCA2 wild-type 
clones. Resistance ratio (R) values ranged from 1.8 to 
2.1 after 72 and 144 h and from 2.0 to 2.4 after 240 h 
of exposure. Similarly, HYDAMTIQ was more active 
in CAPAN-1 cells than in MCF-7 cells. R values ranged 
from 2.7 and 5.6 after all the interval exposure times were 
tested. Overall, a time-dependent inhibitory effect on cell 
growth was observed. Lower IC50 values were associated 
with prolonged time of exposure ( p < 0.05). A similar 
trend was observed for olaparib ( p < 0.05) (Table 1). The 
inhibitory effects of olaparib on cell growth compared to 
HYDAMTIQ were more marked following 72 and 144 h 
of treatment, whereas after 240 h the IC50 values of the 
two drugs were similar.
HYDAMTIQ Inhibitory Effects on the Growth of Tumor 
Cell Lines With Different Status of Microsatellites
The IC50 values of HYDAMTIQ and olaparib in the 
microsatellite stable HT29 and SW630 cell lines (MSS) 
have been compared with those obtained in the micro-
satellite instable HCT-8, HCT-116, LoVo, and DLD-1 
cell lines (MSI). No statistically significant difference 
was observed after 144 (data not shown) or 240 h of 
exposure to HYDAMTIQ or olaparib between cells with 
different MS status (Fig. 1). Furthermore, no difference 
was observed in such cell lines according to the MRE11 
mutational status (Fig. 1).
HYDAMTIQ Inhibitory Effects on the Growth of Tumor 
Cell Lines With Variable Levels of ATM Protein
A panel of colorectal cancer cell lines (HCT-8, H630, 
SW620, LoVo, and HT29) was analyzed for ATM protein 
expression levels by immunofluorescence assay. Among 
the colorectal cancer cell lines, a high degree of variabil-
ity in ATM protein expression was observed. In particu-
lar, H630 cells had the highest level of ATM protein and 
SW620 cells the lowest (H630 > HCT-8 > HT29 > LoVo > 
SW620) (Fig. 2).
Relationships between IC50 values of HYDAMTIQ or 
olaparib obtained at 144 and 240 h in the five colorectal 
cancer cell lines and ATM protein expression levels were 
investigated. Direct associations were observed for all the 
comparisons performed, and statistically significant values 
were obtained between 144-h IC50 of HYDAMTIQ and 
ATM level ( p = 0.0167) and between 144-h (Fig. 3A and C) 
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or 240-h (Fig. 3B and D) IC50 of olaparib and ATM level 
( p = 0.0167 in both cases).
Different sensitivities of colorectal cancer cells to 
PARPIs according to ATM levels is shown in Figure 4. 
Resistance values given by the ratio of the highest ATM 
expression cells (H630) over the lower ATM expression 
cells (SW620) after 240 h of treatment with HYDAMTIQ 
or olaparib were 0.5 and 0.3, respectively (Fig. 4A and B). 
After 144 h of treatment with HYDAMTIQ or olaparib, 
the r values according to the same parameters were 0.4 
and 0.3, respectively (data not shown).
In order to investigate the relationships between 
PARP inhibition and ATM protein expression variability, 
H630 and SW620 cells were exposed to a double IC50 
concentration of HYDAMTIQ for 240 h. Comparison 
of ATM expression levels before and after exposure to 
Figure 1. Inhibition of human colon carcinoma cell growth: dose-dependent effects of HYDAMTIQ (A) and olaparib (B). Black 
curves indicate microsatellite stable (MSS) cell lines [MRE11 wild type (wt)]; blue curves indicate microsatellite instable (MSI) cell 
lines with heterozygous status of MRE11; and red curves indicate MSI cell lines with homozygous mutational status of MRE11. Each 
curve indicates the concentration–cell growth inhibition curve of a single cell line following 240 h of exposure.
Table 1. Inhibitory Effects of HYDAMTIQ and Olaparib on Cell Growth of Tumor Cell Lines 
With Different BRCA1/2 Mutational Status After 72, 144, and 240 h of Exposure
HYDAMTIQ, IC50 (mM) ± SE Olaparib, IC50 (mM) ± SE
72 h 144 h 240 h 72 h 144 h 240 h 
CAPAN-1 16.8 ± 0.3 5.4 ± 0.1 1.9 ± 0.1 9.4 ± 0.8 2.4 ± 0.1 1.9 ± 0.1
n 3 3 3 3 3 3
CAPAN-1 C2-6 30.2 ± 1.0 9.7 ± 0.8 4.3 ± 0.2 13.3 ± 0.8 5.6 ± 0.2 4.4 ± 0.3
r 1.8 1.8 2.3 1.4 2.4 2.4
n 3 3 3 3 3 3
p 0.002 0.037 0.002 0.146 0.0010 0.011
CAPAN-1 C2-12 33.7 ± 1.3 11.6 ± 1.0 4.5 ± 0.1 15.1 ± 0.3 7.7 ± 0.2 4.3 ± 0.1
r 2.0 2.1 2.4 1.6 3.3 2.3
n 3 3 3 3 3 3
p 0.002 0.023 0.001 0.016 0.0001 0.0006
CAPAN-1 C2-14 34.5 ± 1.0 9.7 ± 0.4 3.9 ± 0.1 18.5 ± 2.0 7.6 ± 0.2 3.1 ± 0.2
r 2.1 1.8 2.0 1.5 2.9 1.8
n 3 3 3 3 3 3
p 0.001 0.004 0.001 0.004 <0.0001 0.042
MCF-7 44.7 ± 2.6 30.4 ± 3.4 8.3 ± 0.9 26.1 ± 0.6 19.9 ± 0.9 3.3 ± 0.3
r 2.7 5.6 4.4 2.8 8.4 1.8
n 4 4 3 4 4 3
p 0.007 0.026 0.026 0.003 0.004 0.054
IC50, concentration of drug required to inhibit cell growth by 50%; SE, standard error; r, resistance index; 
n, number of experiments; p, HYDAMTIQ or olaparib IC50 values of CAPAN-1 cells versus CAPAN-1 clones 
or MCF-7 cells.
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HYDAMTIQ showed a decrease, although not statisti-
cally significant, of intranuclear fluorescent ATM protein 
in both cell lines (Fig. 4C and D).
Inhibitory Effects of Combined HYDAMTIQ With 
5-Fluorouracil on Tumor Cell Lines With High  
or Low ATM Protein Levels
H630 and SW620 cells were exposed to 5-FU com-
bined with HYDAMTIQ or olaparib for 144 h. Cell 
growth inhibition was evaluated using H630 and SW620 
IC25 values for 5-FU and IC50 values for HYDAMTIQ 
or olaparib.
There was a synergistic effect obtained following 
exposure to both combinations (i.e., HYDAMTIQ/5-FU 
or olaparib/5-FU, CI: 0.6 or 0.5, respectively) in SW620 
cells, characterized by low ATM level (Fig. 5A and B). 
On the contrary, according to the same experimental con-
ditions, an antagonistic effect was observed in H630 cells 
characterized by high ATM level (CI: 1.3 and 1.6, respec-
tively) (Fig. 5C and D).
DISCUSSION
PARPs are a superfamily of enzymes involved in the 
regulation of cellular processes, such as DNA repair, 
gene transcription, cell cycle progression, cell death and 
genomic stability, and apoptosis1,17,18.
PARP-1 and PARP-2 control single-strand break (SSB) 
repair systems such as base excision repair (BER) and 
nucleotide excision repair (NER) pathways19. PARP-1 is 
also involved in the transcription of mitochondrial pro-
teins20. In addition, PARP-1, PARP-2, and PARP-3 are 
involved in double-stranded break (DSB) repair. In par-
ticular, PARP-3 has been shown to be involved in DSB 
repair, mainly promoting the NHEJ process19. DNA dam-
age repair systems, together with cell cycle checkpoints, 
are the cellular reaction to exogenous and endogenous 
genotoxic injuries that may produce DNA SSBs and 
DNA DSBs. Overall, DDR plays a pivotal role in main-
taining genomic integrity and avoiding the occurrence 
of genomic instability typical of cancer cells. However, 
several examples of aberrant proteins are known today 
[e.g., MRE11 in DSB repair, BRCA1 and BRCA2 in HR 
repair (HRR), and ATM and ATR (i.e., ATM and RAD3 
related) in cell cycle checkpoints]21,22. ATM, ATR, and 
DNA-dependent protein kinases (DNA-PKcs) are the 
most upstream DDR kinases. In response to DNA dam-
age, several proteins are phosphorylated in an ATM- or 
ATR-dependent manner, whereas DNA-PKcs regulate 
a smaller number of targets and play a role, primarily 
in NHEJ23.
Most PARPIs act as competitive inhibitors of NAD 
by interfering at the binding site of the enzyme24 or trap-
ping PARP enzymes at damaged DNA25. In the last few 
years, a significantly increased potency and selectivity 
of PARPIs have been obtained because of the advance-
ments in the knowledge of relationships between chemi-
cal structures and pharmacological activity26,27.
We investigated the antiproliferative properties of the 
PARPI HYDAMTIQ on the growth of a panel of human 
tumor cell lines. HYDAMTIQ is a potent inhibitor of 
PARP-1 and PARP-2 with IC50 values in the nanomolar 
range (IC50 29 and 38 nM, respectively)9. The biological 
Figure 2. Baseline levels of ATM (ataxia-telangiectasia mutated) protein expression in colon carcinoma cell lines. (A) Immuno-
fluorescence staining of cell lines labeled with anti-ATM polyclonal antibody (green) and nuclei (blue) counterstained with DAPI (4,6-
diamidino-2 phenylindole) (40´). Images show the baseline levels of ATM in cell lines. ATM plays a critical role in signaling DNA 
damage to cell cycle checkpoints and DNA repair pathways. (B) Baseline ATM protein level optical density according to the different 
cell lines tested. *au, arbitrary units, mean ± standard error.
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activity of HYDAMTIQ has been so far investigated in in 
vivo inflammatory models only10–12.
Our study showed that HYDAMTIQ and olaparib 
were more active in the BRCA2-mutated CAPAN-1 
human pancreatic cancer cell line than in the wild-type 
BRCA2, cisplatin-resistant CAPAN-1 clones (i.e., C2-6, 
C2-12, and C2-14) and in the BRCA1/2 wild-type MCF-7 
breast cancer cell line. No difference in the activity of 
HYDAMTIQ or olaparib was observed in cell lines with 
different MS or MRE11 status.
HYDAMTIQ and olaparib were more active in SW620 
human colorectal cancer cells characterized by a low ATM 
protein expression than in H630 human colorectal cancer 
cells with high ATM protein levels. Following exposure to 
HYDAMTIQ, ATM protein levels decreased in both study 
cell lines, although a more marked decrease was observed 
in SW620 cells. In the same low- and high-ATM expression 
cell lines, the potential synergistic effect of the combination 
of 5-FU and HYDAMTIQ or olaparib was evaluated. In 
SW620 cells, the combination of 5-FU and HYDAMTIQ 
or olaparib exerted a synergistic effect, whereas an antago-
nistic effect in H630 cells was observed.
The major determinant of the PARPI activity is the pres-
ence of defects in the DNA repair mechanisms of cancer 
cells. In particular, PARPIs are selectively cytotoxic against 
cells with mutations of genes involved in DNA repair 
(synthetic lethality)21,22,28. The absence of defects in DNA 
repair mechanisms does not allow an optimal inhibitory 
effect on the growth of PARPIs. Ovarian, breast, and 
pancreatic cancers with mutations in BRCA1 or BRCA2 
genes involved in the HRR system have been shown to 
be sensitive to the activity of PARPIs both at preclinical 
Figure 3. Correlations between baseline ATM expression and HYDAMTIQ IC50 values in colon carcinoma cell lines. Scatter plots 
indicate relationships between baseline ATM expression and IC50 of HYDAMTIQ at 144 (A) and 240 (B) h or IC50 of olaparib at 
144 (C) and 240 (D) h in cell lines. *au, arbitrary units, mean ± standard error. Black circles indicate the intersection of IC50/ATM 
expression values of a single cell line.
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and clinical levels29. As expected, our results showed a 
more potent activity of HYDAMTIQ in BRCA2-mutated 
cells than in BRCA wild-type cells and are in agreement 
with those reported by Sakai et al.30 concerning the PARPI 
AG014361 in the same in vitro tumor models. Other authors 
also reported a higher activity of different PARPIs, such as 
talazoparib31 or AG01469932, in CAPAN-1 cells or other 
BRCA1/2-mutated or epigenetically silenced BRCA1/2 cell 
lines compared to BRCA1/2 wild-type cell lines.
PARPIs can also contribute to synthetic lethality in 
MSI cancer cells. MSI is a molecular phenotype that arises 
from defects in the DNA mismatch repair (MMR) system. 
Loss of MMR function is due to somatic or germline 
epigenetic/genetic alterations of MMR genes. About 15% 
of colorectal cancers show MSI due to epigenetic silenc-
ing of the MLH1 gene or to germline mutations in mis-
match repair genes (e.g., MLH1, MSH2, MSH6)33. Other 
mutations that contribute to the MSI phenotype may be 
present in oncogenes and tumor suppressor genes, in par-
ticular BRAF34, MRE11 (ATM)35,36, and KRAS37.
Our findings, showing no difference in the activity of 
HYDAMTIQ or olaparib in colorectal cancer cell lines 
as a function of both MS and MRE11 status, are in agree-
ment with those obtained by Genther Williams et al.38, 
who observed no difference in the sensitivity to niraparib 
between MSI-H and MSS colorectal cancer cell lines. 
Figure 4. Dose-dependent effects of HYDAMTIQ and olaparib in SW620 and H630 cell lines and changes of ATM levels following 2 ´  IC50 
HYDAMTIQ treatment. Inhibition of cell growth: dose-dependent effects of HYDAMTIQ (A) or olaparib (B) in cell lines with the highest 
(H630) or the lowest (SW620) level of ATM protein. Inhibitory cell growth effects were evaluated after 240 h of exposure. ATM protein 
expression levels in H630 (C) and SW620 (D) cells exposed to HYDAMTIQ 2 ´  IC50 for 240 h. *au, arbitrary units, mean ± standard error.
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Similar findings were observed by McPherson et al.36 in 
panels of colorectal cancer cell lines with different MS 
status treated with the PARPI LT-626. Conversely, Vilar 
et al.35 showed a higher sensitivity to the PARPI veliparib 
in MSI MRE11 mutated colorectal cancer cells compared 
with MSS MRE11 wild-type colorectal cancer cells. 
Differences observed between our results and those of 
Vilar et al. could be due to the different colorectal cancer 
cells used. In fact, only four out of their eight cell lines 
were included in our seven cell line panel.
The concept of “synthetic lethality” may also be 
extended to ATM that is frequently altered or deleted both 
in solid and hematologic malignancies. Heterozygous 
germline mutations in ATM are associated with leukemia, 
breast, and pancreatic cancers39. ATM is a serine threonine 
kinase that represents a critical component of the early 
response to DNA damage and activation of cell cycle 
checkpoints40. ATM, together with ATR, collaborates with 
the checkpoint proteins Chk2 and Chk1, respectively, to 
arrest the cell cycle and allow DNA repair. Several studies 
have shown that ATM deficiency or ATM harboring muta-
tions confer sensitivity to olaparib in in vitro lymphoid 
tumor models41–43 and in breast44, gastric45, and colorectal46 
cancer cells. The HYDAMTIQ activity results in SW620 
and H630 cells, selected from a panel of human colorec-
tal cancer cell lines on the basis of their ATM protein 
Figure 5. Pharmacodynamic interactions between HYDAMTIQ or olaparib and 5-fluorouracil in SW620 and H630 cell lines. 
Synergistic inhibitory effects of HYDAMTIQ 20 µM (~IC50) (white bar), 5-FU 3 µM (~IC25) (black bar), HYDAMTIQ 20 µM plus 
5-FU 3 µM (gray bar) (A) or olaparib 5 µM (~IC50) (white bar), 5-FU 3 µM (~IC25) (black bar), and olaparib 5 µM plus 5-FU 3 µM 
(gray bar) (B) on the growth of SW620 cells characterized by low levels of ATM after 144 h of exposure. Antagonistic inhibitory 
effects of HYDAMTIQ 45 µM (~IC50) (white bar), 5-FU 1 µM (~IC25) (black bar), HYDAMTIQ 45 µM plus 5-FU 1 µM (gray bar) 
(C) or olaparib 30 µM (~IC50) (white bar), 5-FU 1 µM (~IC25) (black bar), and olaparib 30 µM plus 5-FU 1 µM (gray bar) (D) on the 
growth of H630 cells characterized by high levels of ATM after 144 h of exposure. Data from a representative experiment. The dotted 
line indicates expected growth. CI, observed/expected growth ratio.
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expression levels (i.e., the lowest and highest, respectively), 
are in agreement with data from the studies reported above, 
performed in in vitro models treated by olaparib41,43–46. To 
investigate a potential differential role for ATM protein 
levels according to HYDAMTIQ treatment, we evalu-
ated variations in ATM protein levels in SW620 and H630 
cells pre- and posttreatment. We observed a more marked 
decrease in posttreatment ATM in SW620 cells, suggesting 
that other molecular mechanisms, in addition to ATM, are 
likely involved in resistance to HYDAMTIQ.
In addition to the above-reported conditions, mainly 
represented by defects in DNA repair pathways and DNA 
damage recognition, signaling, and checkpoints system 
that allow PARPIs to exploit synthetic lethality, this phe-
nomenon may also be generated by the concomitant pres-
ence of PARPIs and DNA-damaging agents. In fact, it 
has been observed that the suppression of PARP activ-
ity increases cell susceptibility to DNA-damaging agents 
and inhibits strand break rejoining. Thus, the inhibition 
of PARP could represent an interesting pharmacological 
strategy in order to enhance the effectiveness of DNA 
damage induced, for instance, by 5-FU, a pyrimidine 
antimetabolite that is the backbone of the treatment of 
colorectal cancer both in the adjuvant and metastatic 
setting47. In particular, 5-FU determines imbalances in 
deoxynucleotide triphosphate levels as well as the accu-
mulation of uracil and 5-FU at the genomic level. Such 
events are able to activate the ATR- and ATM-dependent 
checkpoint signaling pathways and the BER pathway.
Although the ATR- and ATM-dependent checkpoint 
signaling pathways are activated by 5-FU, their role in 
the survival of cancer cells treated with this drug is still 
unclear48. The observed synergistic effect of the combi-
nation of 5-FU and HYDAMTIQ or olaparib in SW620 
cells and the observed antagonistic effect in H630 cells 
support the hypothesis that low ATM expression may be 
associated with impaired DNA repair while high ATM 
expression may not be.
To date, few articles have investigated the effects 
of in vitro combinations, including PARPIs and 5-FU, 
with controversial results48–52. Sakogawa et al.50 studied 
the histone variant cH2AX as a marker of DSBs and 
found that combined treatment with 5-FU and the PARPI 
3-aminobenzamide (3-AB) induced cH2AX focus for-
mation with similar increases and kinetics as the single 
treatment with 5-FU in esophageal cancer cells. These 
authors then suggested that, in combination with 5-FU, 
PARPIs would not be able to increase DSB. On the con-
trary, Falzacappa et al.52 showed that PARP inhibition by 
rucaparib enhances the chemosensitization of both mye-
loid (OCI-AML2) and lymphoid (RPMI-8402) leukemia 
cells to 5-FU exposure, suggesting a synergistic effect 
of the combined therapy in killing leukemia cells. Based 
on the above observations, further studies are therefore 
needed to clarify the relationship between ATM, 5-FU, 
and PARPIs.
The results of our in vitro studies have shown that the 
novel PARPI HYDAMTIQ exhibits potent cell growth 
inhibitory activity against a limited number of tumor cell 
lines with relevant defects in DDR pathways. In these in 
vitro models, HYDAMTIQ showed comparable antipro-
liferative effects to olaparib.
The spectrum of antiproliferative activity of HYDAMTIQ 
remains to be determined on a wider panel of tumor types 
with particular reference to human cell lines with defects 
in other HRR proteins recruited by PARP (e.g., XRCC1, 
topoisomerase I). Thus, a molecular target screen of 
HYDAMTIQ in a large cell line set with known muta-
tional profile of genes involved in the DNA repair process 
is warranted and will allow more informed interpretation 
of HYDAMTIQ spectrum of activity.
These results could be of particular clinical relevance 
since genetic/epigenetic alterations of these genes have 
been observed in several types of tumors, providing a 
basis for preclinical and potential clinical development of 
PARP inhibition in tumors other than ovarian and breast 
cancers, such as prostate and pancreatic tumors, and glio-
blastoma multiforme53.
Also, pharmacokinetics/pharmacodynamics (PK/PD) 
and maximum tolerated dose (MTD) studies for 
HYDAMTIQ screening in selected preclinical in vivo 
can cer models are warranted prior to first-in-human tri-
als in patients with mixed solid, refractory, metastatic 
tumors and further potential proof-of-concept trials in the 
chosen tumor settings. It is conceivable that these studies 
are feasible since HYDAMTIQ displays favorable physi-
cochemical and PK properties, in particular a good brain 
penetration supporting, for instance, potential application 
in glioblastoma (Pellicciari, unpublished data).
Clinical development of PARPIs also comprises the 
approach of combining PARPIs with DNA-damaging 
agents to achieve chemosensitization. This is based on 
extensive preclinical studies showing that PARPIs enhance 
the action of temozolomide, cisplatin, topoisomerase I 
inhibitors, and ionizing radiation in tumor cell lines in vitro 
and in mouse xenograft models of human cancers. Our 
study also provides evidence of synergism of HYDAMTIQ 
and a fluoropyrimidine, 5-FU. These findings suggest 
that combining a fluoropyrimidine and a PARPI may be 
an innovative therapeutic strategy for colorectal cancer. 
Phase I and II trials of various PARPIs in combination 
with DNA-damaging agents are ongoing.
In this scenario, it will be interesting to see whether 
HYDAMTIQ is equivalent or superior to the various 
PARP-1/2 inhibitors currently in clinical development as 
either single-agent or combination therapy. Thus, further 
basic studies of this novel potent PARPI are warranted 
and are likely to be informative and worthwhile.
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